Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE MDP 25 versus NEPHROSCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE MDP 25 versus NEPHROSCAN.
DRAXIMAGE MDP-25 vs NEPHROSCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m methylene diphosphonate (MDP) is a bone-seeking radiopharmaceutical. After intravenous injection, it adsorbs onto hydroxyapatite crystals in bone, with increased uptake in areas of high metabolic activity or blood flow, such as tumors or fractures. The technetium-99m emits gamma rays which are detected by a gamma camera for imaging.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
555–925 MBq (15–25 mCi) intravenously for bone scintigraphy; imaging performed 2–4 hours post-injection
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours for the primary complex; minor radiochemical impurities may have longer half-lives
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (urinary excretion of 60-70% as unchanged drug within 24 hours, with 5-10% biliary excretion)
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical